Published in Medical Letter on the CDC and FDA, November 6th, 2005
Recently, CytRx announced the initiation of a phase II clinical trial with orally administered arimoclomol for ALS, and patient identification for this trial is underway at several clinical trial sites. Arimoclomol was granted orphan drug status designation by the FDA for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.